For example, phospholipid nanoparticles (PL1) were found to be effective in delivering costimulatory receptor mRNA (CD137 or OX40) to tumor-infiltrating T cells, and the use of PL1-OX40 mRNA and anti-OX40 antibody was shown to have more significant antitumor activity than anti-OX40 antibody alone in a variety of tumor models [3]. This evidence concerns the gene TNFRSF9 and neoplasm.